Eilidh Robertson’s Post

Looking forward presenting in 2 weeks, for the first time externally, our work on shipments with clinical samples, their carbon footprint, and how we can reduce (and get savings along!)... The title of that Symposium is "Challenges and Solutions of Sample Management": I believe that a challenge (to come) is how we will operate by 2030 in a context of targeted carbon-neutrality (scopes 1, 2 & 3). I will present there one solution we built, which will help a lot in that direction - among others! #environmental #sustainability #shipments #clinical #samples #Novartis

In case you missed it: in this Pharma's Almanac roundtable, a panel of industry experts weighs in on the most significant regulatory decision or guidance influencing biopharma in 2024 and beyond. Read the roundtable here: https://lnkd.in/g-yU58uV Our roundtable includes contributors from GBI Bio, Lonza, MilliporeSigma, PPD, Samsung Biologics, Tedor Pharma Services, ADVI Health, Agilent Technologies, Astrea Bioseparations, Atomic AI, BioBridge Global, BioIVT, BIOSENIC S.A., Bruker BioSpin, Cellares, Cyclacel Limited, eClinical Solutions, Ellab - Validation & Monitoring Solutions, Evonik, Faeth Therapeutics, HDT Bio, Likarda, LGM Pharma, Medicus Pharma Ltd., Mission Bio, MOBILion Systems, Inc., Newfront, Norstella, OM1, Inc., OrganaBio, Organon, Ori Biotech, OzUK, Pharmatech Associates, a USP company, PointClickCare, ScaleReady, SCIEX, SCTbio, Sernova, ...(cont) #Regulatory #Biopharma #Roundtable

🔬🧠 From lead identification to developing a groundbreaking BTK inhibitor, Redx Pharma's success story is a testament to the power of collaboration within our ecosystem. Explore their journey and the impact of precision medicine in our latest whitepaper ➡ http://bit.ly/3XQ26XP

Another great development with iQ-007 performing very well in tox studies toward Phase 1 later this year.

I am honored to have participated in Pharma's Almanac's recent roundtable, where industry leaders discussed the pivotal regulatory decisions shaping the future of biopharma in 2024 and beyond. In my contribution, I highlighted the emerging regulatory framework for generative AI technologies. As we integrate these technologies into drug development and patient care, it is crucial to establish responsible usage guidelines that minimize bias in AI outputs. Read the full roundtable discussion to gain insights from industry experts on the dynamic regulatory landscape that will drive innovation and ensure safety across the sector. https://lnkd.in/g-yU58uV #Biopharma #AI #Innovation #Regulation

Not really. My patent #10,646,535 proves an engineering method which can be used as an intellectual property fence to protect development up botanical new drug. Botanical new drug will be where most of this development occurs. I do agree that cannabis will be somewhat of a novelty soon as we begin REAL research and REAL study of the endocannabinoid system. Why develop with cannabis when you can develop with endocannabinoids? There is no doubt the world changed on 4/30/24...

In a recent survey gathering 206 responses from industry leaders, we uncovered fascinating insights into 32 distinct RBQM practices. More than half of sponsors and CROs have already embraced RBQM approaches, signaling a transformative shift in how we manage risks in drug development. In our latest webinar featuring Ken Getz of Tufts Center for the Study of Drug Development, we explored these numbers. Now, you can watch on-demand: https://bit.ly/440BWmf 🗣 #ClinicalResearch #RBQM #Pharma #Biotech

Attended the PBSS workshop on Human #MassBalance and #MetaboliteProfiling Studies in San Francisco yesterday. Interesting talks by experts from Industry and #FDA. The workshop perfectly covered the strategies, technical approaches (including microtracer AMS), regulatory guidance, applications and case studies. The event was organized by Chandra Prakash, chaired by Shichang Miao and ended with a vibrant Panel Discussion. Thanks to all the speakers: Chandra Prakash (Agios Pharmaceuticals), Bernard Murray (Gilead Sciences), Shuai Wang (Genentech), Ronald Kong (PTC Therapeutics, Inc.), Grace Yan Danielsen (FDA), Ryan Takahashi (Stealth NewCo) and Raman Sharma (Pfizer). #TNO #Peregrion #DMPK #ADME #Bioavailability #MetID #Pharmacokinetics #Bioanalysis #DrugDevelopment.

So you’re looking for GenAI use cases in biopharma… … but you missed our webinar. 😞 Don’t worry, we’ve got you covered. 😉 Join our expert AI panel of Alex Jijie | Digitalya OPS, Jessica Ingram | Camino, and Manuel Mitola, MBA on demand. In this free webinar recording, you will learn all about how you can start with GenAI today. Watch here 👉 https://brnw.ch/21wL66H Psst...👂 We had an amazing Q&A session at the end of the webinar! Check out some of the most pressing questions with answers in the comments below. #magnoliadxp #pharma #biotech #biopharma #genai

In the recent edition, Top Most Innovative Bioanalytical Service Providers to Watch, Insights Care magazine gladly features Altasciences guided by Lynne LeSauteur, PhD, Vice President of Laboratory Sciences, and other prominent bioanalytical service providers. Read More: https://cutt.ly/ReOHCgwg #BioanalyticalServices #InnovationInHealthcare #Biotech #Pharma #HealthcareInnovation #LaboratoryServices #InsightsCare #healthcareinnovationmagazines #onlinehealthcaremagazine #globalhealthcaremagazines